Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory Cd22-positive Acute Lymphoblastic Leukemia (All)

Next Previous
X
Search
Trial Profile

An Open-label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory Cd22-positive Acute Lymphoblastic Leukemia (All)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Cytarabine; Filgrastim; Fludarabine; Mitoxantrone
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms INO-VATE; INO-VATE ALL
  • Sponsors Pfizer

    • Most Recent Events

    • 06 Oct 2023 Results of retrospective pooled analysis of 3 clinical trials( ZUMA-3, INO-VATE, and TOWER)estimating the relative treatment effects of brexu-cel versus inotuzumab ozogamicin (InO), blinatumomab (blina), and chemotherapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients, published in the Advances in Therapy.
    • 01 Sep 2022 Results of a post-hoc analysis assessing subsequent salvage therapies and comparing time from randomization to first subsequent salvage therapy in inotuzumab ozogamicin and standard-of-care chemotherapy published in the Clinical Lymphoma, Myeloma & Leukemia
    • 13 Apr 2022 Results assessing the potential association between leukemic molecular profiles and efficacy of InO, presented at the 113th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top